Medicare Drug Pricing Reform Is A Reality: Here Is What’s On The Agenda
Executive Summary
Congressional Democrats achieved a long-sought goal in passing major legislation to control drug prices in Medicare. A complete lack of Republican support suggests the programs established by the bill will face the same kind of legislative and legal challenges that confronted the Affordable Care Act, which was enacted in a similar manner.
You may also be interested in...
MedPAC’s Message To Congress: Drug Pricing Still Needs Attention
The US Medicare Payment Advisory Commission is continuing its work on proposals to overhaul federal payment for physician administered drugs. That is an ominous message for the biopharma industry as it reels from passage of dramatic pricing legislation earlier this year.
Medicare Part D Price Inflation Rebates Won’t Mean As Much In Inflationary Times
Fewer rebate penalties than lawmakers expected may be assessed in the coming year because of the current high rate of general inflation.
US House Republicans Launch Oversight Of Medicare Price ‘Negotiation’ Program
Offering a glimpse of what to expect if the GOP wins the House in the midterm elections, Reps. McMorris Rodgers and Brady urge transparency from HHS, ask lots of questions, and request monthly briefings on plans for implementation.